NCT07594964 — Shenzhen Xinhe Biomedical cancer immunotherapy trial
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
Registry record
| Registry ID | NCT07594964 ↗ |
|---|---|
| Lead sponsor | Shenzhen Xinhe Biomedical |
| Collaborators | — |
| Phase | Phase 1 |
| Status | Recruiting |
| Indication | Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC), Hepatocellular Carcinoma (HCC), Gastric Cancer (GC) |
| Enrollment | 48 participants (target) |
| Start date | 2025-08-25 |
| Primary completion | 2029-10-30 (est.) |
| Last registry update | 19 May 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07594964), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07594964?
NCT07594964 (To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors) is registered on ClinicalTrials.gov as Phase 1, sponsored by Shenzhen Xinhe Biomedical.
Is NCT07594964 recruiting?
As of the 2026-05-19 registry update, NCT07594964 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07594964?
The lead sponsor is Shenzhen Xinhe Biomedical.
What condition does NCT07594964 study?
The registered conditions are Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC), Hepatocellular Carcinoma (HCC), Gastric Cancer (GC). Primary completion is listed as 2029-10-30 (estimated).
Are results available for NCT07594964?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07594964.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.